Private equity investment firms are setting their sights on orthopaedic care as federal regulators and the industry at large look to move more of these treatments away from hospitals and into outpatient settings.
Healthcare experts are predicting a surge of private equity deals in practices that perform hip and knee replacements in the coming months as transactions are finalized.
"We're right on the precipice of seeing a big wave of these deals," Michael Cole, Managing Director and Healthcare Industry Leader at Alvarez & Marsal’s Transaction Advisory Group, told Healthcare Dive. He said his group is working on four deals right now.
Read more of Mike’s insights in the full article in Healthcare Dive here.
Conversations with Anthony Caporrino: From Diligence to Value: The New CDD Playbook
July 14, 2026
Alvarez & Marsal Commercial Due Diligence Managing Directors Jennifer Holland and Elizabeth Pearsons share what rigorous commercial diligence looks like in practice, and where most PE firms are getting it wrong.
Beyond the Airframe: A Practical Diligence Framework for Drone and Unmanned-Systems Deals
June 25, 2026
Defense investment is accelerating across multiple geographies, and the capital pursuing it is growing at a faster pace. Global venture capital investment in defense technology reached a record $49.1 billion in 2025, nearly double the previous year's total.
Alvarez & Marsal Expands Financial Services Industry Expertise With Senior Transactions Talent in U.S.
May 28, 2026
Alvarez & Marsal (A&M), a leading global professional services firm, today announced the appointment of Val Philippe as a Managing Director within its Global Transaction Advisory Group (Global TAG), continuing the expansion of the firm’s Financial Services capabilities amid growing demand from private equity sponsors and strategic investors for integrated transaction and operational advisory support.
Canada’s Private Capital Outlook 2026: Infrastructure, Insight, and Operational Alpha
May 19, 2026
Canadian private capital enters 2026 in a state of disciplined optimism. The environment is more selective, more data-driven, and significantly more execution-focused than in prior cycles.
